Alpha-fetoprotein as a predictor of liver disease progression in HBV patients with HIV and HCV co-infections

Introduction: Hepatitis B virus (HBV) infection is a significant health challenge globally, especially in sub-Saharan Africa. Co-infections with HIV and HCV worsen HBV-related liver diseases, complicating clinical management. Alpha-fetoprotein (AFP) is a key biomarker for monitoring liver disease progression and detecting hepatocellular carcinoma (HCC). This study evaluates AFP levels in HBsAg and HBeAg seropositive patients with and without HIV and HCV co-infections over one year in Warri, Delta State, Nigeria. This study aimed to understand the impact of HIV and HCV co-infections on liver disease prognosis in HBV patients by evaluating AFP levels and liver function over one year. Materials and Methods: This longitudinal cohort study included 200 HBsAg and HBeAg seropositive patients aged 18-65 years, divided into three groups: HBV monoinfection (n=80), HBV/HIV co-infection (n=60), and HBV/HCV co-infection (n=60). Participants were followed for one year with quarterly blood sample collections for AFP measurement using ELISA, liver function tests (ALT, AST, ALP, bilirubin), and viral load assessments. Sociodemographic data were also collected. Results: AFP levels were significantly higher in the HBV/HCV co-infection group (36.2 ± 12.4 ng/mL) compared to the HBV monoinfection (12.5 ± 4.3 ng/mL) and HBV/HIV co-infection groups (18.7 ± 6.8 ng/mL) (p